Mahdavi Ali, Pejovic Tanja, Nezhat Farr
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine, New York, New York, USA.
Fertil Steril. 2006 Apr;85(4):819-26. doi: 10.1016/j.fertnstert.2005.08.061. Epub 2006 Mar 9.
To critically examine the possible association between ovulation-inducing drugs and ovarian cancer.
Medline literature review and cross-reference of published data.
RESULTS(S): The studies that have adjusted for the effects of confounding factors such as duration of oral contraceptive use and number of pregnancies have noted an increased risk of ovarian cancer among infertile women who remain childless despite long periods of unprotected intercourse. Whether such women are at risk due to the primary basis for their infertility or factors such as ovulation-inducing drugs, has been the subject of several studies. Overall, the findings on ovarian cancer (especially invasive epithelial and non-epithelial) risk associated with fertility drug treatment are reassuring. However, a stronger association between fertility drug use and borderline tumors of the ovary has been observed.
CONCLUSION(S): Despite the overall reassuring findings of the available studies, there is a need for well-designed clinical trials to understand the possible carcinogenic effects of the ovulation-inducing drugs.
严格审查促排卵药物与卵巢癌之间可能存在的关联。
对已发表数据进行医学文献检索及交叉引用。
那些对诸如口服避孕药使用时长和怀孕次数等混杂因素的影响进行了校正的研究指出，在那些尽管长期无保护性交却仍未生育的不孕女性中，卵巢癌风险有所增加。这类女性是因其不孕的主要原因还是诸如促排卵药物等因素而处于风险中，已成为多项研究的主题。总体而言，关于生育药物治疗与卵巢癌（尤其是浸润性上皮性和非上皮性卵巢癌）风险之间的研究结果令人安心。然而，已观察到生育药物使用与卵巢交界性肿瘤之间存在更强的关联。
尽管现有研究的总体结果令人安心，但仍需要精心设计的临床试验来了解促排卵药物可能的致癌作用。
